Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management

(2010) Morie A. Gertz   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

(2010) W. Lamm et al.   ANNALS OF HEMATOLOGY

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

(2010) V. Sanchorawala et al.   BLOOD

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

(2010) P. Moreau et al.   BLOOD

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

(2010) Morie A. Gertz et al.   LEUKEMIA & LYMPHOMA

Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score

(2010) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

(2009) J. A. Vrana et al.   BLOOD

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA